Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for actinic keratosis treatment, effective May 15, 2026. Here's what billing teams need to do.
CMS actinic keratosis treatment policy has been updated. The Centers for Medicare & Medicaid Services has modified its coverage policy governing treatment of actinic keratosis — a common precancerous skin condition managed across dermatology, primary care, and oncology practices. This update carries real financial exposure for practices that bill Medicare for these services. The policy does not list specific codes in the available documentation, but actinic keratosis billing spans a range of CPT and HCPCS codes that your team should audit before the May 15, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Treatment of Actinic Keratosis |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Dermatology, Primary Care, Surgical Oncology, Mohs Surgery |
| Key Action | Audit your actinic keratosis billing protocols and documentation practices before May 15, 2026 |
CMS Actinic Keratosis Coverage Criteria and Medical Necessity Requirements 2026
The CMS actinic keratosis coverage policy governs when Medicare will pay for treatment of this precancerous skin condition. Actinic keratoses are rough, scaly patches caused by years of sun exposure. Left untreated, a percentage progress to squamous cell carcinoma — which is why CMS has long recognized medically necessary treatment as reimbursable under Medicare Part B.
The real issue here is that "medically necessary" does more work in this policy than most billing teams realize. CMS expects documentation that the lesion was clinically evaluated, that the extent and number of lesions support the chosen treatment, and that the treatment selected is appropriate for the clinical presentation. Vague documentation — "treated AK on forehead" — is exactly what triggers a claim denial under medical necessity review.
This policy modification signals that CMS is tightening how it evaluates medical necessity for actinic keratosis treatment. Whether that means stricter documentation thresholds, updated criteria for specific treatment modalities, or revised prior authorization requirements at the Medicare Administrative Contractor level, your billing team needs to read this update carefully before the effective date of May 15, 2026.
The underlying coverage policy has not changed in its fundamental orientation — actinic keratosis treatment remains a covered benefit when medical necessity is established. But the modification means the criteria or documentation requirements supporting that determination have shifted. That's where your exposure lives.
If you're billing through a MAC that has issued a local coverage determination (LCD) for actinic keratosis, check whether that LCD aligns with this CMS update. MACs sometimes lag national policy changes. If there's a conflict between your MAC's LCD and the updated CMS position, flag it with your compliance officer before May 15, 2026.
CMS Actinic Keratosis Exclusions and Non-Covered Indications
The specific policy documentation available here does not enumerate individual exclusions. That said, CMS's general framework for actinic keratosis treatment has historically excluded several categories of services.
Purely cosmetic removal of lesions that are not clinically diagnosed as actinic keratoses is not a covered benefit. If a lesion is documented as a cosmetic concern rather than a precancerous lesion, Medicare will deny the claim. Your documentation must clearly establish the clinical — not cosmetic — rationale for treatment.
Repeat treatments without documented evidence of lesion persistence or new lesion development also draw scrutiny. If a patient returns for a second treatment cycle, your notes need to show why. The prior authorization question matters here too: some MAC-level policies require prior auth for photodynamic therapy and other modalities used in field therapy for actinic keratosis. Check your MAC's LCD before billing.
Coverage Indications at a Glance
The specific policy documentation does not include a detailed indication-by-indication breakdown. The table below reflects the general CMS coverage framework for actinic keratosis treatment, based on known Medicare billing guidelines for this condition.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Clinically diagnosed actinic keratosis — lesion-directed treatment | Covered when medical necessity criteria met | Not specified in this policy update | Documentation must support clinical diagnosis, not cosmetic concern |
| Field therapy (e.g., photodynamic therapy) for widespread actinic keratoses | Covered when medical necessity criteria met | Not specified in this policy update | Prior authorization may be required at MAC level; verify LCD |
| Treatment of actinic keratosis in immunocompromised patients | Covered — often with stronger medical necessity basis | Not specified in this policy update | Clinical notes should document immune status as supporting factor |
| Cosmetic removal of non-AK lesions | Not Covered | N/A | No clinical diagnosis of precancerous change; claim denial expected |
| Repeat treatment without documented lesion persistence | Coverage at risk | Not specified in this policy update | Document new or persistent lesion presentation at each visit |
Note: This table reflects general CMS coverage principles. The policy update does not list specific covered or excluded codes in the available documentation.
CMS Actinic Keratosis Billing Guidelines and Action Items 2026
Here's what to do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull your MAC's current LCD for actinic keratosis treatment. Your MAC may have already updated — or will update — its local coverage determination to reflect this CMS modification. If your MAC's LCD hasn't changed yet, watch for updates through April and early May 2026. Billing against an outdated LCD after the CMS effective date is a claim denial waiting to happen. |
| 2 | Audit your documentation templates for medical necessity language. Your notes must establish clinical diagnosis of actinic keratosis, number and location of lesions, treatment rationale, and — for field therapy — why lesion-directed treatment isn't sufficient. If your current EHR templates don't prompt for this, update them before May 15, 2026. |
| 3 | Verify prior authorization requirements with your MAC before billing photodynamic therapy. Photodynamic therapy for field cancerization is a higher-reimbursement service that MACs scrutinize closely. If your MAC requires prior auth, get it in place before the claim goes out. A missing prior authorization is an avoidable write-off. |
| 4 | Train your coding staff on the distinction between lesion-directed and field-directed treatment. These are billed differently. The number of lesions treated, the area of skin involved, and the treatment modality all drive code selection. Sloppy code selection in actinic keratosis billing is a consistent audit trigger. |
| 5 | Check for any updated ICD-10 diagnosis code requirements. CMS policy modifications sometimes come with changes to acceptable diagnosis codes. The policy documentation available here does not list specific ICD-10 codes — but confirm with your MAC whether any diagnosis code requirements have changed under this update. |
| 6 | Review your charge capture process for any services rendered at or after the May 15, 2026 effective date. Claims for actinic keratosis treatment with dates of service on or after May 15 will be evaluated under the modified policy. Services rendered before May 15 use the prior criteria. Make sure your billing system reflects this cutoff cleanly. |
| 7 | If your practice has high volume of Medicare actinic keratosis claims, loop in your compliance officer now. Don't wait until May 14. High-volume practices face proportionally higher denial exposure when a policy modification is ambiguous. A pre-effective-date review of your billing practices takes hours. Unwinding a pattern of post-May-15 denials takes months. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Actinic Keratosis Treatment Under This CMS Policy
The policy documentation available for this update does not list specific CPT, HCPCS, or ICD-10 codes. This is worth flagging directly: the absence of a code list in the policy document does not mean codes are unaffected. It means you need to confirm with your MAC which codes fall under this coverage policy.
Do not apply codes from other sources — including this post — as a substitute for reviewing the actual updated policy document and your MAC's LCD.
What to Confirm With Your MAC
Your MAC should be your first call after the CMS update publishes in full. Ask specifically:
- Which CPT codes are covered under the updated criteria for actinic keratosis treatment?
- Has the LCD been updated to align with this CMS modification?
- Are there new prior authorization requirements for any treatment modalities?
- Are there updated ICD-10 diagnosis code requirements for covered claims?
Until those questions are answered directly, treating any code list as final is premature.
General Actinic Keratosis Billing Context
Practices that bill Medicare for actinic keratosis treatment typically use codes spanning destruction of benign or premalignant lesions, photodynamic therapy, and related evaluation and management services. The number of lesions, treatment method, and body area all drive code selection under standard dermatology billing guidelines. None of these code assignments are impacted in ways we can confirm without the full updated policy text.
If your billing team needs a complete code-level breakdown, access the full policy at payerpolicy.org as the document becomes available, or watch for your MAC's LCD update.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.